Patrick Greatrex, Vice President Business Development at Gambro said, Gambro is very excited to co-operate with Dipylon in developing their cardiac monitoring system. The collaboration offers Gambro the opportunity to leverage its leading membrane technology know-how into new diagnostic and therapeutic application areas.
Måns Alfvén, CEO of Dipylon says, Gambro’s world-leading expertise in membrane technology has been instrumental in the development of our unique system. The collaboration has enabled us to launch the system, celebrate our first export success and raise additional growth capital financing to enable full commercialization.
The system consists of a catheter which is implanted into the venous outflow of the heart, whereby Gambro’s membrane technology is used to monitor biochemical processes which are predicative of infarcts and heart failure. The system is cleared for up to 48 hours of continuous monitoring and intended for intensive care use.
